MASLD/MASH represents a growing clinical and economic burden, with MASH conferring heightened risks of advanced fibrosis, cirrhosis, hepatocellular carcinoma, and liver-related mortality. Noninvasive ...
Targeted therapies for MASH show progress, with pegozafermin leading in efficacy for fibrosis regression and disease resolution. New research highlights the effectiveness of targeted therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results